APA (7th ed.) Citation

SM, T., M, B., JT, B., A, C., EC, D., SL, P., . . . MP, G. (2022). Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study. Frontiers in oncology, 11, 810023. https://doi.org/10.3389/fonc.2021.810023

Chicago Style (17th ed.) Citation

SM, Tolaney, et al. "Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study." Frontiers in Oncology 11 (2022): 810023. https://doi.org/10.3389/fonc.2021.810023.

MLA (9th ed.) Citation

SM, Tolaney, et al. "Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study." Frontiers in Oncology, vol. 11, 2022, p. 810023, https://doi.org/10.3389/fonc.2021.810023.